The REGN CEO was referring to neutralizing antibodies against multiple covid19 variants. This is a very different mechanism of action he is referring to compared to Leronlimab. That said, the immune modulatory action of Leronlimab I think fits a longhaulers need although Cyrus has made it clear Covid indications are in the rear view mirror for now. Never say never but near term Cyrus is going to go with stated targets HIV, NASH, Cancer) in a disciplined way.